MARKET

IGC

IGC

IGC Pharma Inc
AMEX
0.2897
-0.0003
-0.10%
Pre Market: 0.2876 -0.0021 -0.72% 07:33 05/29 EDT
OPEN
0.2887
PREV CLOSE
0.2900
HIGH
0.2898
LOW
0.2802
VOLUME
2.68K
TURNOVER
45.92K
52 WEEK HIGH
0.4985
52 WEEK LOW
0.2420
MARKET CAP
29.00M
P/E (TTM)
-4.5336
1D
5D
1M
3M
1Y
5Y
1D
"Science & HealthMarijuana Components Have 'Consistent' Anti-Tumor Effects In Glioblastoma And Other Cancers, Scientific Review Shows" - Marijuana Moment
Benzinga · 2h ago
Weekly Report: what happened at IGC last week (0518-0522)?
Weekly Report · 4d ago
New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, and Global Workforce Technology
Barchart · 6d ago
IGC Pharma GAAP EPS of -$0.02 in-line, revenue of $0.32M beats by $0.09M
Seeking Alpha · 05/19 21:32
Weekly Report: what happened at IGC last week (0511-0515)?
Weekly Report · 05/18 09:37
New to The Street's Show #753 Airs Nationwide on Bloomberg Television Across the U.S., MENA and Latin America Featuring FreeCast (NASDAQ:CAST), Stardust Power (NASDAQ:SDST), Lost Soldier Oil and Gas, Virtuix Holdings (NASDAQ:VTIX), and Medicus Pharma
Barchart · 05/16 02:00
IGC Pharma to present new Tau-PET biomarker research at Global Tau conference
TipRanks · 05/15 13:00
Weekly Report: what happened at IGC last week (0504-0508)?
Weekly Report · 05/11 09:35
More
About IGC
IGC Pharma, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) to develop treatments for Alzheimer's and metabolic disorders. The Company's lead asset, IGC-AD1, is a cannabinoid-based therapy is in a Phase 2 trial (CALMA) for agitation in Alzheimer's dementia. The Company’s pipeline includes TGR-63, targeting amyloid plaques, and early-stage programs focused on neurodegeneration, tau proteins, and metabolic dysfunctions. The Company integrates AI to accelerate drug discovery, optimize clinical trials, and enhance patient targeting. It is also developing a Multimodal Interpretable Transformer for Alzheimer’s Disease (MINT-AD). MINT-AD leverages diverse data sources, including brain scans, genetics, lifestyle, and cognitive metrics, to produce clinically interpretable risk profiles and forecast decline trajectories.

Webull offers IGC Pharma Inc stock information, including AMEX: IGC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IGC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IGC stock methods without spending real money on the virtual paper trading platform.